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Alpha-1 acid glycoprotein (AGP) is a highly glycosylated plasma protein that exerts vasoprotective eﬀects. We hypothesized that
AGP’s N-linked glycans govern its rate of clearance from the circulation, and followed the disappearance of diﬀerent forms of radi-
olabeled human AGP from the plasma of rabbits and mice. Enzymatic deglycosylation of human plasma-derived AGP (pdAGP) by
Peptide:N-GlycosidaseFyieldedamixtureofdiﬀerentiallydeglycosylatedforms(PNGase-AGP),whiletheintroductionofﬁveAsn
toGlnmutationsinrecombinantPichiapastoris-derivedAGP(rAGP-N(5)Q)eliminatedN-linkedglycosylation.PNGase-AGPwas
cleared from the rabbit circulation 9-fold, and rAGP-N(5)Q, 46-fold more rapidly than pdAGP, primarily via a renal route. Pichia
pastoris-derivedwild-typerAGPdiﬀeredfrompdAGPinexpressingmannose-terminatedglycans, and,likeneuraminidase-treated
pdAGP, was more rapidly removed from the rabbit circulation than rAGP-N(5)Q. Systemic hyaluronidase treatment of mice tran-
sientlydecreasedpdAGPclearance.AGPadministrationtomicereducedvascularbindingofhyaluronicacidbindingproteininthe
livermicrocirculationandincreaseditsplasmalevels.OurresultssupportacriticalroleofN-linkedglycosylationofAGPinregula-
ting its in vivo clearance and an inﬂuence of a hyaluronidase-sensitive component of the vessel wall on its transendothelial passage.
1.Introduction
Alpha-1 acid glycoprotein (AGP; also known as orosomu-
coid) is a 44kDa, heavily glycosylated protein synthesized
primarily byhepatocytesandsecreted into theplasma,where
it circulates under normal conditions in humans at 8–30μM
[1, 2]. During the acute phase response, circulating levels
of human AGP are elevated over baseline values by 2- to
7-fold [3]; in rats, rabbits, and mice, the elevation of either
circulating AGP or hepatic AGP mRNA ranges from 10- to
200-fold [4–8]. The biological function of AGP is unclear.
Suggested roles for this plasma protein include the mod-
ulation of the immune response [9]; the stabilization of
plasminogenactivatorinhibitor-1(PAI-1)functionalactivity
[10]; and the maintenance of normal capillary permeability
and selectivity [11].
Evidence from perfusion or cell culture systems supports
a role for AGP in maintaining capillary permselectivity. Per-
fusion studies using isolated rat skeletal muscle [12] or kid-
neys [13]o rf r o gm e s e n t e r i cp r e p a r a t i o n s[ 14] initially
showed that the rate of negatively charged protein loss from
the perfusate (e.g., albumin or lactalbumin) was reduced in
the presence of AGP. These ﬁndings lead to the hypothesis
that AGP binds to the capillary vessel wall and increases its
negative charge [14]. AGP binding to endothelial cells in cul-
ture has also been demonstrated [15–17]. The protein has
furthermore been suggested to form part of the glycocalyx,
a dynamic endothelial surface layer of glycosaminoglycans,2 Journal of Biomedicine and Biotechnology
proteoglycans, and adsorbed plasma proteins deduced by
indirect examination, for instance as a red cell exclusion
zone in intravital microscopy [18]. Most recently, transfused
human AGP was shown to exert renal eﬀects by restoring
normal glomerular ﬁltration rates in rats rendered nephrotic
by puromycin aminoglycoside administration [19].
It has long been known that enzymatic removal of termi-
nal sialic acid residues, and exposure of terminal galactose
moieties, converts AGP into a high-aﬃnity ligand of the
asialoglycoproteinreceptor,leadingtoitsrapidremovalfrom
the mammalian circulation [20–23]. Relatively few studies,
however, have examined the in vivo clearance of the unmodi-
ﬁed plasma glycoprotein [24–26] ,a n dn o n eh a v ee x a m i n e d
the consequences of complete removal of glycans on the
clearance and catabolism of AGP. Since AGP is a relatively
small protein of approximately 43kDa, with 45% of its mass
being contributed by its carbohydrates, we hypothesized that
removal of its sugars would render it ﬁlterable in the kidneys
and accelerate its clearance from the circulation[27]. In the
current study, we tested this hypothesis and in addition
investigated the consequences to AGP clearance of systemic
disruption of the glycocalyx.
2.MaterialsandMethods
2.1. Materials. Aﬃ-Gel Blue chromatography resin and Bio-
Gel HT hydroxyapatite resin were purchased from Bio-Rad
Laboratories (Hercules, CA). Concanavalin A (Con A),
Sepharose 4B, and T4 DNA ligase were from GE Healthcare
(Piscataway, NJ). Reverse transcription reagents RNEasy
and Sensiscript RT kits and heat-stable HotStarTaq DNA
polymerase were from Qiagen (Chatsworth, CA). Neurami-
nidase, peptide N-glycosidase:F (PNGase F), and Phusion
heat-stableDNA polymerasewerepurchased fromNew Eng-
land BioLabs (Ipswich, MA). Streptomyces hyaluronidase,
commercial AGP, goat antihuman AGP antibodies, and alka-
line phosphatase conjugated anti-goat IgG were from Sigma
(St. Louis, MO). A Glycan Diﬀerentiation kit was pur-
chased from Roche Applied Science (Mannheim, Germany).
Biotinylated hyaluronic acid binding protein was from
Associates of Cape Cod (East Falmouth, MA). Alexa Fluor
488 labeling kits, streptavidin conjugated Alexa Fluor 647,
Alexa Fluor 488-Griﬀonia simplicifolia lectin-1B4(GS-1B4),
Pichia pastoris strain X-33 and Zeocin, ThermalAce high
ﬁdelity DNA polymerase, the pcDNA 3.1 vector, and E. coli
DH5α cells were all purchased from Invitrogen Corporation
(Carlsbad, CA). Restriction and DNA modiﬁcation enzymes
were supplied by either Fermentas Life Sciences (Burlington,
ON), or Fisher Scientiﬁc (Unionville, ON). HepG2 (human
hepatocellular carcinoma) cells were obtained from the
American Type Culture Collection (Manassas, VA). Na125I
for radioiodination was from Perkin Elmer Life Sciences
(Boston, MA).
2.2. Experimental Animals. Experiments involving animals
were carried out under the terms of Animal Utilization Pro-
tocols approved by the Animal Research Ethics Board of the
Faculty of Health Sciences of McMaster University. Rabbits
(New Zealand White, 2.1 to 2.8kg, male and female, speciﬁc
pathogen-free) were purchased from Charles River (St.
Constant,Quebec),aswereC57Black6(C57Bl/6)malemice
of 20–30g body weight.
2.3. Puriﬁcation of AGP from Human Plasma. AGP was puri-
ﬁed exactly as described by Herv´ e et al. [28]f r o mc i t r a t e d
plasma obtained from healthy volunteer donors, collected
with informed consent using a protocol approved by the
Hamilton Health Sciences Research Ethics Board. The
plasma pool was combined, using equal volumes from each
donor, aliquoted and frozen at −80◦C until use; the same ﬁve
donors (4 Caucasian, 1 Black) were used for all preparations
employed in this study.
2.4. Enzymatic Modiﬁcation of AGP. The terminal sialic acid
chains of puriﬁed AGP were removed by treatment with
Clostridium perfringens neuraminidase, using 5 units of en-
zyme per μg of AGP in 50mM sodium citrate, pH 6.0, over-
night at 37◦C. Entire N-linked glycan chains were removed
from AGP using Peptide: N-Glycosidase F (PNGase F). For
electrophoretic use, AGP (0.02mg) was denatured by boiling
in 0.5% SDS, 80mM dithiothreitol for ten minutes, then
reacted with 2500 units PNGase F at 37◦ for one hour, after
dilution into 1% NP-40, 50mM sodium phosphate pH 7.5.
For radiolabeling and in vivo use, 0.2mg AGP in 5.0M urea
was incubated for one hour at room temperature, then
diluted 1:1 with 10,000 units of PNGase F in 0.1M sodium
phosphate pH 7.5, and incubated overnight at 37◦C, prior to
dialysis against phosphate buﬀered saline.
2.5.DNAManipulations. AhumanAGPcDNAwasobtained
by reverse transcription/PCR of HepG2 cell mRNA, employ-
ing RNEasy and Sensiscript RT kits (Qiagen) and oligonu-
cleotide primers ML13047 (5 -GAATGGATCCAAGGT-
GACTGCACCCTGC-3 ) and ML13048 (5 -ATCGAATTCG
GTACACATGT CGGGTTGG-3 ). The product was sub-
cloned into pUC19, yielding plasmid pUC19-AGP. The
latter plasmid was ampliﬁed using Phusion polymerase
under conditions recommended by the manufacturer (New
England Biolabs), and sense oligonucleotide primer 07-1495
(5  ACGTCTCGAGAAAAGACAGATCCCATTGTGTGC-
CAACC-3 ) and antisense oligonucleotide primer 07-1493
(5  CAGTGAATTC CTAGTGATGG TGATGGGATTCCCC-
CTCCTC CTGTTT-3 ). The resulting PCR product was
restricted with XhoI and EcoRI and inserted between these
sites in yeast expression vector pPICZ9ssamp [29]t of o r m
pPICZ9ssAGPH6. This plasmid was modiﬁed by PCR in
site-directed mutagenesis reactions that altered 5 Asn (N)
codons 15, 38, 54, 75, and 85 to Gln (Q), forming pPIC-
Z9ssAGP-N(5)Q-H6. All DNA constructs were veriﬁed by
DNA sequencing (MOBIX, McMaster University) prior to
expression and utilization of recombinant AGP.
2.6. Expression and Puriﬁcation of Recombinant AGP. Plas-
mids pPICZ9ssAGPH6 and pPICZ9ssAGP-N(5)Q-H6 were
separately used to transform Pichia pastoris X33 yeast to
Zeocin resistance, and resulting cell lines were cultured andJournal of Biomedicine and Biotechnology 3
induced with methanol; conditioned media was neutralized
and secreted recombinant proteins were puriﬁed by nickel
aﬃnity chromatography, as previously described [30].
2.7. In Vivo Clearance of AGP in Rabbits. Puriﬁed plasma-
derived,enzymaticallytreated,orrecombinantformsofAGP
were iodinated using the Iodogen method [31] and injected
into the marginal ear vein of rabbits, as previously described
[32]. At timed intervals (0.083, 0.5, 1, 2, 4, 6, 8, 24, 48,
72, 96, and 168 hours or until the recovered radioactivity
declined lower than 0.1% of the injected dose) blood sam-
ples were taken from the marginal vein of the other ear, cen-
trifuged to obtain plasma, and the trichloroacetic acid-pre-
cipitable radioactivity was determined by γ counting. For
each rabbit, semilogarithmic substrate disposition graphs of
residual plasma radioactivity against time were generated,
and analyzed using PK Solutions version 2.0 software (Sum-
mit Research Services, Montrose, CO, USA). Brieﬂy, the soft-
ware was employed to ﬁt the data using noncompartmental
(area)methodsbasedonthetrapezoidrule.Forthispurpose,
radioactive doses were converted into pmoles using the
measured speciﬁc activity of radiolabeling, and molecular
weights of 43, 33, and 23kDa for pdAGP, PNGase-AGP,
and rAGP N(5)Q, respectively. The speciﬁc activity of radio-
labeling was similar for all three proteins, ranging from
3.94 to 7.05 X 106cpm/μg. In some experiments, the tissue
distribution of radioactivity 30 minutes after intravenous
injection of radioiodinated AGP or derivatives was measured
as described [33]; brieﬂy, organs were excised, rinsed in
ice cold saline, weighed, and either a portion or the entire
organ, depending on its size, was γ counted. Results were
expressed as a fraction of the total radioactive dose injec-
ted. In other experiments, either 4.0g of α-methyl-D-man-
nopyranoside (α-methyl-mannoside) in 20mL sterile saline,
or 0.54g of D-galactose in 10mL sterile saline, was injected
intraperitoneally immediately prior to intravenous injection
of radioiodinated protein in an eﬀort to block glycan-depen-
dent uptake via hepatic receptors.
2.8. In Vivo AGP Clearance in Mice. Clearance of radio-
labeled human AGP in C57Bl/6 mice was followed as pre-
viously described [30, 34] by measuring acid-precipitable
plasma radioactivity in plasma samples. Plasma radioactivity
was reported as percentage of the injected dose, using as a
dilution factor the plasma volume divided by the sample
volume. Plasma volume was calculated as the product of
the weight of the mouse in grams X 0.078mL blood vol-
ume per gram body weight X (1-the hematocrit), using
a hematocrit of 0.44 (US NIH reference values from
http://oacu.od.nih.gov/ARAC/). In some experiments the
mice were treated with Streptomyces hyaluronidase (Sigma-
Aldrich, St. Louis, MO, USA) by intravenous injection of
47U (to deliver 30U/mL estimated plasma volume) of the
enzyme in 0.1mL sterile saline coinjected with iodinated
human AGP.
2.9. Intravital Microscopy. Anesthetized mice (20–30g body
weight) were cannulated via the right jugular vein, the
abdomen opened, and a lobe of the liver placed on the
heated Plexiglas stage of a Leica DMI 6000 B confocal micro-
scope. The liver microvasculature was photographed using a
Hamamatsu C9100-12 back-thinned EMCCD camera atta-
ched to a Leica DMI 6000 B confocal microscope using the
63X objective. Either 15μg biotinylated bovine hyaluronic
acid binding protein (bHABP) complexed to streptavidin-
conjugated Alexa Fluor 647 (Associates of Cape Cod, Fal-
mouth, MA, USA) or 40μg Griﬀonia simplicifolia 1B4 (GS-
1B4,) lectin directly conjugated to Alexa Fluor 488 (Invitro-
gen, Carlsbad, CA, USA) was injected through the cannula
into the vasculature. Baseline images were obtained over the
next 15 minutes, then hyaluronidase was injected as des-
cribed above, and images were acquired for an additional
hour. In some experiments puriﬁed human AGP (165mg/kg
body weight) was injected after bHABP:streptavidin Alexa
Fluor 647 administration and baseline image capture and 15
minutespriortohyaluronidasetreatment.Fluorescentinten-
sity was quantiﬁed using ImageJ software (http://rsb.info.nih
.gov/ij/).
2.10. Ligand Blotting. The ability of various forms of AGP to
react with digoxigenin-labeled lectins was assessed following
SDS-PAGE and electrical transfer of proteins to nitrocellu-
lose; blots were analyzed using a DIG Glycan Diﬀerentiation
Kit as suggested by the manufacturer (Roche Diagnostics,
Mississauga, ON, Canada).
2.11.StatisticalAnalysis. Dataarereportedasthemean ±the
standard deviation in all cases. Statistical analysis was per-
formed using GraphPad Instat version 3.06 software (Graph-
Pad Software Inc, San Diego, CA), using one-way Analysis of
Variance (ANOVA) for multiple comparisons and Student’s
t-testsforpairedcomparisons.Nonparametricmethodswere
employed if data did not pass tests of normality and equiv-
alence of standard deviation; further details are provided in
Figures 1–6 and Table 1.
3. Results
The in vivo clearance of AGP treated with neuraminidase
to remove the terminal sialic acid residues has been widely
investigated, to a greater extent than that of the unmodiﬁed
protein [21, 24, 35, 36]. We ﬁrst ensured that our puriﬁed
AGP behaved as expected following this enzymatic modiﬁ-
cation. As shown in Figure 1(a), neuraminidase treatment
increased the electrophoretic mobility of AGP and elimi-
nated its recognition by Sambucus nigra agglutinin (SNA),
which binds to sialic acid linked to galactose. Five minutes
after injection, 45.5 ± 4.0% of the injected AGP was detected
in plasma, compared to 0.77 ± 0.36% of neuraminidase-
treated AGP, a diﬀerence of 82-fold. By ﬁfteen minutes, the
proportion of AGP remaining in the circulation was unchan-
ged for native AGP (42.0 ± 5.5%) but had further declined
to0.25 ±0.5%inthecaseoftheneuraminidase-treatedform
(Figure 1(b)).
Enzymatic and recombinant DNA methods were used to
reduce or eliminate the number of N-linked glycan chains4 Journal of Biomedicine and Biotechnology
Table 1: Pharmacokinetic parameters relating to AGP clearance in rabbits.
Form of AGP
pdAGP PNGase-AGP (PNGase-treated) rAGP N(5)Q
Area under the curve (AUC 0-∞) (in pmol-hr/mL) 11 ± 15 . 8 ± 0.9 0.74 ± 0.07∗∗∗
Mean residence time (MRT; in hr) 73 ± 65 7 ± 32 3 ± 6∗∗∗
Volume of distribution (Vdiss; in mL/kg) 190 ± 20 700 ± 100∗∗∗ 6000 ± 1000∗∗∗
Steady state volume of distribution (Vss; in mL/kg) 160 ± 20 550 ± 90∗∗∗ 2000 ± 500∗∗∗
Clearance (CL; mL/hr/kg) 2.23 ± 0.03 11 ± 2∗∗∗ 100 ± 10∗∗∗
Half-life calculated from Vdiss a n dC L( h o u r s ) 5 8± 45 0 ± 34 2 ± 9∗∗
Themean ±thestandarddeviationisshown(n = 6).DerivativesofAGPwerecomparedtothecorrespondingAGPvalueusingone-wayANOVAwithTukey’s
post-test; ∗∗indicates P<0.01, ∗∗∗indicates P<0.001.
attached to AGP. Denaturation of AGP was required to ob-
tain any signiﬁcant reduction in its extent of glycosylation
using PNGase F, which removes glycan chains in their enti-
rety at their point of attachment to asparagine residues on
thepolypeptidebackboneofAGP.Enzymaticdeglycosylation
following denaturation of AGP with urea or SDS was com-
pared. As shown in Figure 2, transient denaturation with
urea allowed the partial removal of 0–5 glycans per AGP
molecule; full denaturation with SDS removed all glycans.
That the most rapidly migrating PNGase F reaction prod-
uct of AGP was fully deglycosylated was indicated by its
comigration both with SDS and PNGase F-treated AGP, and
with a form of recombinant AGP mutated to abrogate N-
linked glycosylation (rAGP N(5)Q) (Figure 1(a)), and by the
loss of recognition of all of these putatively deglycosylated
species with SNA lectin (data not shown). In keeping with its
intermediate state of deglycosylation, PNGase F-treated AGP
exhibited more rapid clearance in rabbits than unmodiﬁed
AGP, but was retained in the circulation to a greater extent
than rAGP N(5)Q; these diﬀerences were apparent as early as
30 minutes after injection (Figure 2(b)). Electrophoresis and
autoradiography of postinjection plasma samples revealed
that the most rapidly migrating deglycosylated forms of AGP
(e.g., “1” versus “2” in Figure 3(b)) were lost from plasma
more rapidly than less rapidly migrating forms (e.g., “3”
or “4” in Figure 3(b)). In terms of organ distribution, both
PNGase F-treated AGP and rAGP N(5)Q were found in
the kidney to a greater extent than native AGP, the eﬀect
being more pronounced for the fully deglycosylated form
(Figure 3(d)).
The diﬀerences in clearance of the three forms of AGP
were apparent not only on substrate disposition versus time
graphs, such as those shown in Figure 2, in which the pro-
teins were compared on the basis of residual radioactivity,
but also following pharmacokinetic analysis, in which the
proteinswerecomparedbasedupontheirdoseinpmolesand
their residual plasma concentration in pmol/mL (Table 1).
PNGase-AGP and rAGP N(5)Q exhibited decreased areas
under the clearance curve, decreased mean retention times,
and decreased half-lives, but the decreases were only statis-
tically signiﬁcant for rAGP N(5)Q. The volumes of distri-
bution and clearance rates were signiﬁcantly increased for
both altered forms (e.g., mean CL was increased 4.9-fold for
PNGase-AGP and 45-fold for rAGP N(5)Q, P<0.001 versus
pdAGP in both cases).
We produced recombinant nonglycosylated AGP N(5)Q
in a Pichia pastoris yeast expression system [29]. The disap-
pearance of injected radiolabeled rAGP-WT from the rabbit
circulation, which like rAGP-N(5)Q, was C-terminally hex-
ahistidinylated to facilitate puriﬁcation, but which unlike the
mutated AGP, retained all ﬁve sites of N-linked glycosylation,
was also examined. As shown in Figure 4(a),r A G P - W T
was much more rapidly removed from the circulation than
its mutant rAGP-N(5)Q counterpart. Thirty minutes after
injection of equal doses of either radiolabeled rAGP-WT or
rAGP N(5)Q, the residual plasma concentration of the latter
exceededtheformerbymorethan10-fold(Figure 4(a);2.2±
0.5% versus 26 ± 3%, P<0.0001 by unpaired t-test, Welch
corrected). Coadministration of α-methylmannoside, but
not galactose, signiﬁcantly reduced the loss of rAGP-WT
from the circulation (to 6 ± 1%, P<0.05 by Kruskal-Wallis
test); neither sugar signiﬁcantly altered the concentration of
rAGP N(5)Q in the circulation, suggesting that the yeast
glycans contained terminal mannose residues (Figure 4(a)).
Electrophoresis showed that rAGP-WT migrated more rapi-
dlythanpdAGP,consistentwithitsmodiﬁcationwithshorter
N-linked glycans than in plasma-derived AGP (Figure 4(b)),
and ligand blotting showed that rAGP-WT, but not plasma-
derived human AGP, bound Galanthus nivalis agglutinin
(GNA), which is a lectin speciﬁc for glycans terminating in
mannose residues (Figure 4(b)). In contrast, rAGP-N(5)Q
was unreactive with all lectins, consistent with its intended
lack of glycosylation (data not shown).
Intravenous administration of hyaluronidase prior to in-
jection of radiolabeled AGP changed both its recovery and
distribution in mice for several hours after treatment. Ini-
tially,therecoveryofAGProsefrom80.2 ±5.8intheabsence
of hyaluronidase to 96.8 ± 6.0 (P = 0.0007 by two-
tailed unpaired t-test); as seen in Figure 5, the elevation of
AGP in the plasma in hyaluronidase-treated mice remained
detectable until 3 hours after treatment. The area under the
observed curve (t = 0t ot = 6 hours) was increased from
250 ± 30%-hr to 300 ± 30%-hr (P = 0.037 by two-tailed
unpaired t-test) by hyaluronidase treatment. We next sought
independent conﬁrmation that hyaluronidase was having its
intended eﬀect on the murine vasculature, using intravital
confocal microscopy of livers of mice treated with or with-
outhyaluronidase.Treatmentwiththeenzymereducedsinu-
soidalvesselstainingwithﬂuorescentlylabeledHABPbutleft
vascularbindingbyﬂuorescentGS-1B4 unchanged(Figure 6,Journal of Biomedicine and Biotechnology 5
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Figure 1: Neuraminidase treatment of human AGP increases its clearance from the rabbit circulation. Plasma-derived AGP with (neu-AGP)
or without (AGP) neuraminidase treatment was examined on a 12% SDS reducing gel, either by Coomassie Blue staining ((a), left, stained
gel) or by ligand blotting with SNA ((a), right, SNA blot). The position of molecular mass markers is shown in kDa, at left. Tfn: transferrin;
GST: glutathione sulfotransferase. (b) Shows the recovery (% injected dose) of acid-precipitable radioactivity in plasma at diﬀerent times
following injection of radioiodinated AGP (solid bar) or neu-AGP (open bar) into rabbits. ∗Indicates P<0.05 versus corresponding AGP
value by unpaired t-test, Welch corrected. The mean of 7 determinations ± SD is shown.
compare (a) to (b) and (d) to (e)). The distribution of HABP
was also altered by administration of 3.3mg intravenous
human AGP (10-20 times endogenous AGP levels) without
hyaluronidase treatment. This intervention left 5- to 6-fold
more HABP in the plasma column than in the absence of
AGP treatment (Figures 6(c) and 6(f)). Although hyaluro-
nidase treatment altered the clearance and distribution
of AGP, and AGP injection increased HABP retention in
plasma, AGP did not bind to immobilized hyaluronan in
vitro in microtiter plates, unlike HABP, which demonstrated
avid binding (data not shown).
4. Discussion
In this study we explored the eﬀects of altered, diminished,
or absent glycosylation of AGP on its in vivo clearance.
Althoughneuraminidase-treatedAGP(alsocalledasialoAGP
or asialoorosomucoid) has been widely employed for many
years as an injectable ligand and competitor for the hepatic
asialoglycoprotein receptor in vivo [21, 24, 35, 36], the clea-
rance of glycosylated AGP has been less extensively exam-
ined. Regoeczi et al. [24] reported a terminal catabolic half-
life of 68.5 hours for iodinated human AGP injected into a
single3.8kgrabbit;thisvalueissimilartoourﬁndingof59 ±
4h o u r s( m e a n± SD, n = 6, range 53–65 hours, weight range
2.52–2.79kg). Some of the diﬀerence may derive from our
use of noncompartmental modeling and pharmacokinetic
software, as opposed to the compartmental model and man-
ual calculation employed in the older report; alternatively,
our use of lighter rabbits may also be a contributing factor.
In this regard, others employing noncompartmental analysis
of AGP clearance in rats reported steady state weight-adjus-
tedvolumesofdistributionsimilartothatobservedinrabbits
in this study. For pdAGP in rabbits, we observed 160 ±
20mL/kg, while others reported 150mL/kg [37]a n d9 0±
30mL/kg [26]. Taken together, these comparisons suggest6 Journal of Biomedicine and Biotechnology
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Figure 2: Forms of AGP with reduced or absent N-linked glycosylation are cleared from the rabbit circulation more rapidly than native AGP
following intravenous injection. (a) Shows a Coomassie blue-stained 12% SDS reducing gel loaded with 5–10μg per lane of human serum
albumin, HSA; AGP; AGP treated with PNGase F (PNGase) in the presence of either urea (PNGase-AGP (U) or SDS (PNGase-AGP (S);
or recombinant yeast-derived nonglycosylated AGP (rAGP N(5)Q). (b) Depicts the residual acid-precipitable radioactivity remaining in
the plasma of rabbits after intravenous injection of the indicated radiolabeled proteins as a function of time; for each protein, plasma
radioactivity is presented as the percentage of the injected radioactive dose recovered in plasma at the indicated time after injection. Each
point is the mean ± SD of 6 determinations; in most instances error bars are smaller than the symbol that denotes the mean.
that our clearance ﬁndings with respect to pdAGP are rea-
sonable in light of previous reports in the literature and form
a sound basis for comparison to the novel deglycosylated
f o r m so fA G Pt h a tw eg e n e r a t e d .
We used two strategies to reduce or eliminate entire N-
linked glycans from AGP: enzymatic treatment with PNGase
F, or mutation of the ﬁve asparagine residues to which the
glycans are ordinarily attached. The enzymatic strategy was
complicated by the resistance of AGP to deglycosylation in
the absence of treatment with SDS. We elected to employ
urea, since it could be removed by dialysis, promoting re-
folding, as opposed to SDS, which binds tightly to proteins
and cannot readily be removed. PNGase F treatment was
only partially eﬀective in altering AGP clearance, likely due
tothepresenceofsomeunaltered,multiplyglycosylatedAGP
in the mixture; however, the least glycosylated forms of AGP
in that mixture were most rapidly removed from the circula-
tion. A more convincing diﬀerence between native AGP and
nonglycosylated AGP was achieved via the mutational strat-
egy; nonglycosylated rAGP-N(5)Q exhibited a 15-fold dec-
reaseinareaundertheclearancecurve(extrapolatedtoinﬁn-
ity) and a 45-fold increase in clearance rate compared to
plasma-derived AGP. Although it was not possible to control
the rAGP-N(5)Q experiments with wild-type recombinant
AGP made in the same experimental system, due to the high
mannose-type glycosylation typical of yeast, our results were
consistent with previous data. These data were obtained
by investigators who employed metabolic labeling of rat
hepatocytes in the presence of an inhibitor of N-linked gly-
cosylation(tunicamycin)andimmunoaﬃnitypuriﬁcationto
obtain nonglycosylated rat AGP [38]. Although the diﬃculty
in obtaining radiolabeled AGP by this route prevented
replication and kinetic analysis in this study, the 50% dose
retention time was noted to decrease from 100 minutes to 5
minutes for nonglycosylated AGP, as compared with native
AGP, consistent with our ﬁndings, as was increased renal
clearance of nonglycosylated AGP [39].
Having shown that appropriately terminated N-linked
glycans keep AGP from exhibiting accelerated clearance
either via glomerular ﬁltration or via hepatic receptors spe-
ciﬁc for abnormal glycosylation, we turned to the issue of
AGP interaction with the vessel wall. Intravenous adminis-
tration of hyaluronidase to hamsters led to a decrease in the
FITC-Dextran 70 permeation zone deﬁned using intravital
microscopy [40], one consistent with degradation of the
glycocalyx, a surface layer of glycosaminoglycans, proteo-
glycans, and adsorbed plasma proteins [18, 41] thought to
contain AGP [42, 43]. While hyaluronidase treatment of
rabbits would have been ideal in the context of this study,
wefoundsuchtreatmentimpracticalinthislargerlaboratory
animal. In mice, we found that hyaluronidase treatment dec-
reased the initial clearance of AGP, an eﬀect consistent with
anAGP-glycocalyxactionasanormalpartofitsdistribution.
Hyaluronidase treatment appeared to be speciﬁc in that
HABP binding to liver sinusoidal vessels was reduced, but
that of GS-1B4,a nα-galactose-speciﬁc lectin that mainly
binds to animal endothelial cells [44], was unaﬀected. AGP
administration also increased the amount of HABP found
in the plasma column within liver sinusoids. This increase
could have occurred due to AGP binding to hyaluronan inJournal of Biomedicine and Biotechnology 7
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Figure 3: Forms of AGP with reduced glycosylation are cleared from the rabbit circulation and distribute to the kidneys more rapidly than
native AGP. Plasma from rabbit injected with radioiodinated proteins (identiﬁed below (a)–(c)) was electrophoresed on reduced SDS-PAGE
gels; autoradiograms of samples taken 5 and 15 minutes after injection are shown. Molecular mass markers in kDa are shown at left, and the
deduced number of N-linked glycan chains at right. (d) Shows the percentage of the total radioactive dose of injected radioactivity found in
the organs (identiﬁed below the panels) 30 minutes after injection of AGP (solid bars) or PNGase F-treated AGP (PNGase-AGP, open bars)
or rAGP-N(5)Q (stippled bars). The mean of 6 determinations ± SD is shown. ∗Indicates P<0.001 versus AGP value for the other two
proteins within each organ sampled; all other comparisons to AGP values within organs are not signiﬁcant.
the glycocalyx, or its binding to a component of the glyco-
calyx that aﬀected the access of HABP to hyaluronan. We
favour the second explanation because we were unable to
detect AGP-hyaluronan binding in vitro; nevertheless, we
cannot exclude the possibility that this interaction occurs in
vivo. Although our primary reason for examining the liver
microcirculation was technical in that this organ is amenable
to intravital microscopy [45], it has also been shown that
this microcirculatory bed is greatly enriched in hyaluronan
as opposed, for instance, to those of lung or heart [46]. Our
results support the suggestion that AGP is a component of
the glycocalyx, as previously suggested [17, 42, 47, 48].
From a biotechnological point of view, our results also
provide novel information with respect to targeting of re-
combinant AGP to either renal or hepatic destinations. AGP
is a member of a protein family known as the lipocalins
[49]. Lipocalins bind many drugs and metabolites within
a central binding pocket of the polypeptide. Interestingly,8 Journal of Biomedicine and Biotechnology
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Figure 4: Recombinant AGP glycosylated in Pichia pastoris yeast is rapidly removed from the rabbit circulation via mannose receptors.
(a) Shows the radioiodinated rAGP-WT or rAGP N(5)Q remaining in the plasma of rabbits 30 minutes after injection, without (no sugar)
or with coadministered α-methylmannoside (+α MM) or D-galactose (+ Galactose). The mean and SD of 5–7 determinations are shown;
∗indicates P<0.05 versus the corresponding “no sugar” condition by Kruskal-Wallis test. The proportion of the two proteins remaining
in plasma in the absence of added sugar was also compared; ∗∗∗indicates P<0.001 by unpaired t-test, Welch corrected. (b) (Gel) shows a
Coomassieblue-stained12%SDSreducinggelloadedwith5–10μgperlaneofAGP(plasma-derived);rAGP-WT;carboxypeptidaseY(CPY);
and glutathione sulfotransferase (GST). Molecular mass marker positions, shown at left, correspond to: 100; 90; 80; 70; 60; 50; 40; 30; 25;
and 20kDa. (c) (GNA blot) is a blotted replicate of the gel shown in (b), probed with GNA lectin.
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Figure 5: The disappearance of injected AGP from the plasma of
mice following intravenous injection is altered by systemic hyaluro-
nidase treatment. Radioiodinated AGP was injected into mice with
(AGP + hy’ase) or without (AGP) concurrent hyaluronidase treat-
ment, and acid-precipitable radioactivity, shown as the percentage
ofthedoseremaininginplasma,wasfollowedovertime,n = 6±SD.
in this regard lipocalin libraries have been described with
engineered binding properties [50]. Our biological distribu-
tion results raise the possibility that engineered AGPs with
deﬁned ligand binding speciﬁcities could be directed to renal
or hepatic destinations using either the N(5)Q mutant, or
mannosylated rAGP-WT produced in yeast. In the latter
instance, producing AGP (e.g., for conjugation to DNA, as
has been previously reported for gene targeting [51, 52])
or an AGP fusion protein in Pichia pastoris could provide
hepatic targeting in a single step, without the need for neur-
aminidase treatment.
This study had several limitations. It would have been
preferable to use homologous rabbit AGP or murine AGP in
rabbitsandmice,respectively,butoureﬀortstoisolaterabbit
AGP by adapting a protocol designed for the puriﬁcation of
rat AGP [53] were not successful, and it was impractical
to purify suﬃcient quantities of murine AGP from murine
plasma for our purposes. Our study was also limited to
human AGP puriﬁed from the plasma of healthy individuals,
and clearance was similarly investigated in healthy animals.
As such, our results do not address the possibility that
AGP glycosylation or clearance properties are altered during
inﬂammation, as has been suggested [54–56]. Our use of
plasmapuriﬁedfromasmallpoolofhealthydonorstopurify
AGPwasalignedwiththeconceptthatthismaterialmightbe
afuturetherapeuticproductofplasmafractionation[57,58].
Our results show that N-linked glycosylation of AGP is a
critical contributor to its plasma residency, in that reducing
the number of glycans accelerated clearance; this was most
clearly demonstrated for a mutant AGP completely lacking
N-linked glycans. In this regard, AGP resembles antithrom-
bin, in which mutation of any one of four sites of N-linked
glycosylation has been shown to lead to accelerated clea-
ranceinvivoinrabbits[59],butnotalbumin,inwhicheither
naturally occurring [60] or engineered sites of N-linked gly-
cosylationacceleratetheclearanceoftheplasmaprotein[33].Journal of Biomedicine and Biotechnology 9
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Figure 6: Either systemic hyaluronidase treatment or AGP administration reduces HABP binding to the vessel wall of mouse liver sinusoids
in vivo. Mice were treated with hyaluronidase (Hy’ase; (b) and (e)) or without hyaluronidase (no treatment; (a) and (d)) after injection of
either ﬂuorescent HABP complex or ﬂuorescent GS-1B4 and visualization of liver sinusoids by confocal intravital microscopy. (c) Is an
image of an experiment in which AGP intravenous injection was substituted for hyaluronidase. (f) (Mean of n = 3 ± SD) quantiﬁes the
intrasinusoidal HABP ﬂuorescence in the experiment shown in (c) and in three additional replicates; each replicate is the mean of four
intravascular samples within microscopic ﬁelds similar to that seen in (c); ∗signiﬁes P<0.05 by unpaired t-test, Welch corrected.
Glycosylation thus contributes to maintaining a circulating
pool of AGP for exchange into the glycocalyx, where it may
contribute to the maintenance of vascular permeability.
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